Piper Sandler: Transformative License Transaction, Raised Aclaris (ACRS.US) target to $13

Generado por agente de IAMarket Intel
martes, 19 de noviembre de 2024, 1:20 am ET1 min de lectura
ACRS--
PIPR--

Aclaris Therapeutics (ACRS.US) shares rose 53% to $3.14 on Monday after the biopharmaceutical company announced it had secured exclusive rights to two immunotherapy candidates from Biosion, prompting Piper Sandler to upgrade the company's rating.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios